Compare CRSR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | SLS |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 616.0M | 706.7M |
| IPO Year | 2020 | 2007 |
| Metric | CRSR | SLS |
|---|---|---|
| Price | $5.18 | $4.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | 1.5M | ★ 6.3M |
| Earning Date | 05-05-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,480,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $4.48 | $0.95 |
| 52 Week High | $10.41 | $6.14 |
| Indicator | CRSR | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 50.39 |
| Support Level | $4.48 | $1.48 |
| Resistance Level | $6.19 | $5.01 |
| Average True Range (ATR) | 0.29 | 0.52 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 0.00 | 14.93 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.